Aridis Pharmaceuticals Inc (CE) (ARDS) 시세

This is a short sellers dream. They never have to cover.

I think this news is helpful for an Institutional investor.



https://ih.advfn.com/stock-market/NASDAQ/aridis-pharmaceuticals-ARDS/stock-news/91740076/form-424b5-prospectus-rule-424b5

Correct

Ok ths it’s just delisted from Nasdaq

Trading OTC as of today

How you know

Delisted…

Same here

It’s called “sweet” dilution

I loaded up quite a few. Bring it down again, I got a lot more powder

Dip and rip $$$

Load em up $$$$

Load it up I smell greenery…

Got in looks good

Its a buy it an forget it play, 10 yrs from now it could be 50$ a share

Might get to dollar land here

$ARDS - Up 33% Pre-Market/ Current Price $0.35
Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

coming off .26


what madness


maybe WAINWRIGHT S-1 dilution?

https://dilutiontracker.com/app/search/ARDS

.444 BOUGHT THE DIP

Was just a matter of time good luck

phase 3 multi dollar news?

There she goes

Huge! Love it. Thanks!

https://ih.advfn.com/stock-market/NASDAQ/aridis-pharmaceuticals-ARDS/stock-news/91586928/aridis-receives-agreement-from-the-european-medici

Added

No worries here

Adding dips

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review status
LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill hospitalized patients.

"To our knowledge, AR-301 is the very first antibacterial biologics to be awarded the QIDP designation, marking a significant milestone not only for Aridis but also for companies with biologic solutions to fighting antimicrobial resistance (AMR)," stated Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals. "Our AR-301 program will now benefit from the FDA's priority review, in addition to previously awarded Fast-Track status, allowing for accelerated drug development and regulatory review processes. This sought-after designation positions our AR-301 program extremely well as we continue to advance it through a confirmatory Phase 3 trial and license application."

Part of the Food and Drug Administration Safety and Innovation Act, FDASIA (June 2012), Title VIII – Generating Antibiotic Incentives Now (GAIN), the QIDP designation was created to encourage the development of treatments for antibiotic-resistant organisms known to cause serious or life-threatening infections. Recently, The Food and Drug Omnibus Reform Act of 2022 (FDORA), signed on 29-Dec-2022 as part of the Consolidated Appropriations Act, 2023, amends GAIN to expanded QIDP eligibility to include biological products.

An estimated one million patients annually are affected by ventilator associated pneumonia (VAP) that occurs in hospitalized patients receiving respiratory support, which is one of the most frequent ICU-acquired infections. AR-301 specifically targets S. aureus alpha-toxin, which has been implicated in the pathogenesis of pneumonia caused by S. aureus bacteria.

Aridis received positive feedback from the FDA in May 2023 on the Company's proposed single confirmatory Phase 3 study of AR-301. In addition to agreeing to the study required to support the submission of a Biologics License Application (BLA), the FDA agreed to the proposed expansion of the confirmatory Phase 3 study in S. aureus VAP patients to include ventilated hospital-acquired pneumonia (HAP) and ventilated community-acquired pneumonia (CAP) patients.

$ARDS - Up 64%/ Current Price $0.45
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

Watch the MAGIC

im seeintg these types of biotechs tend to RS often

Useless in this market

ZERO BORROW !!!no shares to short

1 daÿ wonder

1 daÿ wonder

Push over 1$

News today

ARDS https://ir.aridispharma.com/news-releases/

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

https://www.nasdaq.com/market-activity/spos

ARDS
Aridis Pharmaceuticals, Inc.
5/22/2023
$3,000,000

Low blow down

Damn 52 week low .15 cents LOL

ards vs ther

Ther goood news big pharma will tk over soon.with cancer

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

Damn, New 52 week lows .34 cents

They're broke... Today's share offering is a pretty good indicator of that much

LOOK FOR A BUYOUT IN THE 4-5$ RANGE.

yes sir, I sold premarket this morning

GOOD NEWS.....BUT FAILING MOMENTUM.

ARDS....................https://stockcharts.com/h-sc/ui?s=VDRM&p=W&b=5&g=0&id=p86431144783

Woke Banks hosting drag shows 100 ——> 1

Treating CF 1 —- > 100